Recently, we had the LACDR PhD Introductory course on Drug Research for starting PhD candidates. It was great to have this live event live in castle Oud Poelgeest, after two years of restrictions.

At the end of February, we had the PhD Introductory Course on Drug Research for starting PhD candidates from LACDR. This 3-days event took place at Castle Oud Poelgeest, a great location to be completely out of the work environment. We welcomed 30 PhD candidates, with whom we had an inspiring and…

Due to the great influx of PhD candidates, we had the pleasure to organize a 2nd PhD Introductory Course on Drug research this year. From November 4- 6, we welcomed 30 participants for this 3-days event, which took place at Castle Oud Poelgeest.

This week, we had the LACDR PhD Introductory course on Drug. This is always a great opportunity for starting PhD candidates to get to know LACDR, CHDR, the Clinical Pharmacology department of LUMC and the embedding of the institute in the BioSciencepark as a whole.

Due to the corona pandemic and the uncertainty of the circumstances end of January 2022, is decided to postpone the LACDR PhD introductory course.

The PhD introductory course will take place on 30 May, 31 May and 1 June 2022 in castle Oud Poelgeest. We are very happy that it will be a live event (as it stands now).

Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.

Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

Leiden researchers, led by Sebastian Pomplun developed a new method to screen hundreds of thousands of molecules for drug discovery, using mass spectrometry instead of DNA tags. ‘We wanted to make drug discovery faster and more accessible.’

Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.

On 4 May, Leiden University remembered the victims of the Second World War from our university community. Alumni, students and present and former staff of the University came together for this Hour of Remembrance.

Medical drugs are expensive to make and can have an adverse effect on the environment. Researchers Stefano Cucurachi and Justin Lian have developed a framework to help the healthcare system assess the economic and environmental sustainability of medical compounds.

PhD defence

Polypeptide Therapeutic Solutions (PTS), a leader in the design, development and custom manufacturing of polyamino-acid based delivery systems for therapeutic drugs and the Leiden Academic Centre for Drug Research (LACDR) today announced a research collaboration to develop advanced drug delivery systems…

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Willem Jespers started his position as Assistant Professor in the group of Prof. G.J.P. van Westen on June 1st, a short introduction below:

Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…

PhD candidate Mengxu Zhang (Division of Systems Pharmacology and Pharmacy) published a comprehensive and important review on “The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure” in Drug Metabolism Reviews.

On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…

Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’

A new government, conflicts around the world and obviously a lot of science: these are the five stories about Leiden University that you enjoyed reading in 2024.

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.